The present research evaluated the antidiabetic and antioxidant properties of M. lucida stem bark (50 and 500mg/kg) and glibenclamide (25mg/kg, standard drug) in acute (Oral glucose tolerance test) and sub-acute (Streptozotocin 60mg/kg, i.p. diabetic model) administration. A group of healthy rats constituted the normal control. The sub-acute experiment lasted 28 days during which water, food intake and weight gain were measured and biochemical parameters analyzed in both plasma and erythrocytes at the end of the experiment. The chemical substances present in M. lucida bark extract were determined. In the Oral glucose tolerance test, the reduction of blood glucose level was statistically significant for both M. lucida extracts and glibenclamide. However, in the diabetic rats acute administration of 500mg/kg extract had better blood sugar lowering effect than glibenclamide, which was better than 50mg/kg extract. Streptozotocin diabetic animal model was characterized by a decrease in weight gain, erythrocyte SOD and CAT activities and an increase in water and food consumption, lipid peroxidation, cholesterol, triglycerides, plasma glucose, creatinine and urea concentrations, and transaminases activities. M. lucida extract and glibenclamide significantly prevented the alteration of these parameters, thus indicating a corrective effect on diabetes and its complications. This study justifies the traditional claim and provides a rationale for the use of M. lucida to treat diabetes. Its antioxidant properties may serve to curb oxidative stress and hence prevent the diabetic complications related to oxidative stress. Chemical substances, which may be accountable for the antidiabetic and antioxidant properties of M. lucida were detected in the aqueous extract of M. lucida bark.